Nuvalent, Inc.

NASDAQ:NUVL

Biotechnology

Healthcare
$123.96 -0.02%

-$0.03 today

Market cap
$9.13B
Beta
1.15
P/E (TTM)
-21.6
EPS (TTM)
-$5.72
52W Low $71.13High $123.62

Volume 0.00M

Average 1.91M

NUVL Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Nuvalent, Inc.NASDAQ: NUVL

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 78.67M shares rose 9.9% year over year, ahead of the +9.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 4.7% from the prior quarter. Over 3 fiscal years it compounded at +13.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +9.9% holds above the trailing-twelve-month pace of +9.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
78.67M+4.7% QoQ
Last fiscal yearDec 2025
72.69M+9.5% YoY
LTMMar 2026
74.44M+9.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.9%——
1 year+9.5%——
3-year CAGR+13.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
72.69M USD
Year-over-year change
+9.5%
4-year CAGR
+35.2%

Weighted Avg Shares (Diluted) vs competitors

How NUVL compares with its peers on the latest reported figures

  • NUVL's LTM Mar 2026 weighted avg shares (diluted) of 74.44M shares is the 5th highest of the 9 companies compared; the peer median is 82.17M shares.
  • Its year-over-year change of +9.1% is the 2nd highest of 9, against a peer median of +6.9%.
  • Over three fiscal years its annual growth of +13.5% compares with a peer median of +8.8%.
NUVL Competitors Peer median
Weighted Avg Shares (Diluted) for NUVL and competitors
Company Period LTM YoY 3-year CAGR
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026142.03M +6.4%+9.9%
PCVXVaxcyte, Inc.LTM Jun 2026139.07M +7.3%+28.0%
CYTKCytokinetics, IncorporatedLTM Jun 2026124.44M +5.1%+10.2%
CRSPCRISPR Therapeutics AGLTM Sep 202694.81M +8.4%+5.0%
NUVLNuvalent, Inc.LTM Mar 202674.44M +9.1%+13.5%
ABVXAbivax S.A.FY202569.53M +10.3%+53.9%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 202668.12M +7.8%+7.6%
JAZZJazz Pharmaceuticals plcLTM Sep 202665.3M +6.5%-0.8%
AXSMAxsome Therapeutics, Inc.LTM Jun 202650.84M +4.3%+7.0%
Peer median (excluding NUVL) 82.17M+6.9%+8.8%

Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.56M63.73M113.24M217.77M306.97M
Selling, General & Admin10.26M22.38M36.25M62.59M107.34M
Operating Expenses45.82M86.11M149.49M280.37M414.31M
Depreciation & Amortization215K00280.37M414.31M
EBITDA(46.12M)(81.85M)(126.22M)20.38M(10.49M)
EBITDA Margin—————
Operating Income(45.82M)(86.11M)(149.49M)(280.37M)(414.31M)
Operating Margin—————
Interest Income0023.27M38.32M44.74M
Interest Expense0023.27M00
Other Income / Expenses(521K)4.25M23.27M20.38M(10.49M)
Income Before Tax(46.34M)(81.85M)(126.22M)(259.99M)(424.79M)
Pre-Tax Margin—————
Income Tax Expense000764K585K
Net Income(46.34M)(81.85M)(126.22M)(260.76M)(425.38M)
Net Margin—————
EPS (Basic)(2.13)(1.65)(2.17)(3.93)(5.85)
EPS (Diluted)(2.13)(1.65)(2.17)(3.93)(5.85)
Weighted Avg Shares21.78M49.67M58.22M66.41M72.69M
Weighted Avg Shares (Diluted)21.78M49.67M58.22M66.41M72.69M

Nuvalent, Inc.

NASDAQ:NUVL

Intrinsic Alpha fair value

Locked

Current Price

$123.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.